Advertisements


Oil & Gas Stock Roundup Headlined by Chevron & Diamondback

Apart from Chevron (CVX) and Diamondback Energy (FANG) there was news from Royal Dutch Shell (RDS.A), Helmerich & Payne (HP) and Suncor Energy (SU) during the week. It was a week when oil prices bounced back above $70 and natural gas futures registered their highest settlement since February 2014.On the news front, American biggie Chevron CVX broke down its future shift toward an environmentally friendly direction, while shale specialist Diamondback Energy FANG approved a new buyback plan.Overall, it was another good week for the sector. West Texas Intermediate (WTI) crude futures moved up 3.2% to close at $71.97 per barrel and natural gas prices gained 3.4% to reach $5.105 per million British thermal units (MMBtu). Overall, both commodities managed to maintain their forward momentum from the previous three weeks.Coming back to the week ended Sep 17, oil prices rose, underpinned by a report from the Energy Information Administration ("EIA") that showed draws in crude and fuel stockpiles. The commodity was also boosted by the major international forecasters’ encouraging view on oil demand growth next year.Natural gas climbed too, buoyed by the slow restoration of hurricane-affected operations, late-season hot weather and strong LNG export demand.Recap of the Week’s Most-Important Stories1.  At its recent environment-themed presentation titled Energy Transition Spotlight, Chevron said that it will invest 200% more in lower-carbon businesses in the next seven years but stopped short of committing any timeline toward achieving net-zero operations.The U.S. oil major set clear targets to ramp up renewable natural gas output to 40,000 million British thermal units (MMBtu) per day by 2030, while growing hydrogen production to 150,000 tons annually. Besides, the company is rapidly expanding its renewable fuels footprint with daily production capacity estimated to reach 100,000 barrels by the end of this decade, in addition to increasing carbon offsets to 25 million tons per year.As part of this plan, the American energy giant will invest $10 billion in clean energy through 2028, more than triple the $3 billion earmarked earlier. Of the total, $3 billion each will be spent on renewable fuels and carbon capture/storage/offsets, $2 billion on hydrogen, while $2 billion is planned to be used to reduce the emissions intensity of the company’s portfolio. (Key Highlights From Chevron's ESG Investor Day)2.   Shares of Diamondback Energy gained more than 3% on Sep 17, a day after the energy player stated that its plans to distribute 50% of free cash flow to investors were expedited. Beginning fourth quarter of this year, this Permian producer’s business will return free cash flow through its basic dividend and additional shareholder return methods.In order to support this return promise, the Midland, TX-headquartered independent energy firm’s board approved a new share repurchase program worth $2 billion, which was implemented with immediate effect. The move underscores the company’s sound financial position and its commitment to reward its shareholders.A much-improved commodity price scenario and the economic recovery contributed to the balance sheet strength of the energy companies like Diamondback. Benefiting from their robust fundamentals, their cash from operations is now covering capital spending. This provides a sustainable financial framework for these firms to increase cash returns to their shareholders. (Diamondback Shares Gain on $2B Buyback Acceleration)3.  Royal Dutch Shell (RDS.A) has made a final investment decision to construct an 820,000-tonne-per-year biofuels facility at the Shell Energy and Chemicals Park Rotterdam in the Netherlands. When completed, the plant will be one of the largest in Europe for producing sustainable aviation fuel (SAF) and renewable diesel from trash.The new plant will help the Netherlands and the rest of Europe in meeting the globally mandated carbon reduction goals. It will also assist the Zacks Rank #2 (Buy) Europe-based energy multinational in meeting its objective of becoming a net-zero emissions energy firm by 2050, in line with society's progress toward the Paris Agreement's climate targets.You can see the complete list of today’s Zacks #1 Rank stocks here.The biofuels plant in Rotterdam is anticipated to start producing in 2024. Using innovative technology created by Shell, it will manufacture low-carbon fuels such as renewable diesel from waste in the form of used cooking oil, waste animal fat, and other agricultural and manufacturing residual items. (Shell to Build Dutch Biofuels Facility to Cut Emissions)4.   Helmerich & Payne HP recently announced a strategic collaboration with The Abu Dhabi National Oil Company (“ADNOC”) and its subsidiary ADNOC Drilling Company wherein ADNOC Drilling will purchase eight FlexRig land rigs from the contract drilling services provider for $86.5 million. Following this buyout, the company will make a $100-million cornerstone investment in ADNOC Drilling's recently announced initial public offering (“IPO”).Earlier, ADNOC expressed its plan to list a 7.5% minority stake in ADNOC Drilling on the Abu Dhabi Securities Exchange in an IPO, reflecting the continuous development, strength and relevance in the Middle Eastern capital city's financial market. ADNOC, a renowned diversified energy and petrochemicals company, and Helmerich & Payne will remain ADNOC Drilling's dedicated, long-term stockholders.The above agreement will help Helmerich & Payne achieve its goal of deploying capital worldwide, especially in the MENA (Middle East and North Africa) area, by boosting its entry into the lucrative and rapidly-rising Abu Dhabi market as a vital platform for further regional expansion. (Helmerich & Payne to Pump $100M Into ADNOC Drilling IPO)5.  Suncor Energy SU recently reached agreements with eight indigenous communities in the Regional Municipality of Wood Buffalo to buy the entire 15% equity stake in Canada's Northern Courier Pipeline Limited Partnership held by TC Energy TRPThe partnership, which comprises Suncor, three First Nations, and five Métis communities will hold a 15% interest in this pipeline asset worth roughly C$1.3 billion, which will generate long- term, consistent earnings that will aid the communities for decades ahead.Suncor will run the pipeline that connects its Fort Hills oil production in Alberta to its East Tank Farm asset after the acquisition is completed. Canada's premier integrated energy company stated that the collaboration is projected to generate gross revenues of around C$16 million per year for its partners and offer stable income. Subject to usual closing conditions and regulatory clearances, the deal is expected to be completed in the fourth quarter of 2021. (Suncor, Indigenous Partners Buy Canadian Pipeline Stake)Price PerformanceThe following table shows the price movement of some major oil and gas players over the past week and during the last six months.Company    Last Week    Last 6 MonthsXOM              +2.2%                -4.1%CVX               +0.7%               -7.5%COP              +5.7%               +13.6%OXY               +7.8%               -7.4%SLB               +5.7%               -2.6%RIG                -4%                   -11.9%VLO               +3.5%               -12.5%MPC              +3.5%               +8.4%The Energy Select Sector SPDR — a popular way to track energy companies — was up 3.2% last week. The best performer was oil and gas producer Occidental Petroleum OXY whose stock climbed 7.8%.Over the past six months, the sector tracker has inched up 0.6%. Upstream biggie ConocoPhillips (COP) was the major gainer during the period, experiencing a 13.6% price appreciation.What’s Next in the Energy World?As the global oil consumption outlook strengthens amid tightening fundamentals, market participants will be closely tracking the regular releases to watch for signs that could further validate the upward momentum. In this context, the U.S. government’s statistics on oil and natural gas — one of the few solid indicators that come out regularly — will be on energy traders' radar. Data on rig count from the oilfield service firm Baker Hughes, which is a pointer to trends in U.S. crude production, is closely followed too. News related to coronavirus vaccine approval/rollout/distribution will be of utmost importance. Finally, investors will be keeping an eye on the health of China’s economy following the Evergrande crisis. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.Click here for the 4 trades >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chevron Corporation (CVX): Free Stock Analysis Report Royal Dutch Shell PLC (RDS.A): Free Stock Analysis Report Helmerich & Payne, Inc. (HP): Free Stock Analysis Report Occidental Petroleum Corporation (OXY): Free Stock Analysis Report Suncor Energy Inc. (SU): Free Stock Analysis Report TC Energy Corporation (TRP): Free Stock Analysis Report Diamondback Energy, Inc. (FANG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 23rd, 2021

Where to buy a PlayStation 5 - sign up for a chance to buy one directly from Sony during the holidays

The PlayStation 5 continues to be in high demand, but we've got the latest details on restocks and tips for finding the console online and in stores. When you buy through our links, Insider may earn an affiliate commission. Learn more. Sony's PlayStation 5 remains hard to find months after its release. Sony Sony's PlayStation 5 launched with two models- the $500 standard PS5 and a $400 digital edition. The PS5 remains difficult to find, but retailers like Best Buy and GameStop restock regularly. Sony has also opened a registration program for gamers to purchase the PS5 by invitation. Table of Contents: Masthead StickyPlayStation 5 (small)Playstation 5 (All-Digital) (small)The PlayStation 5 is Sony's fastest-selling video game console ever, with more than 10 million systems sold since its launch in November 2020. However, the record demand and an international chip shortage have made the PS5 one of the hardest items to buy in stores or online.In October, Sony launched a registration program to give shoppers a chance to purchase the PS5 directly from the company during the holiday shopping season. Sony says console supply will remain limited through the end of the year, but a select number of people who register will receive an email to make a direct purchase. You can find more details and register on Sony's site.We've seen weekly restocks of the PS5 ($500) and PS5 Digital Edition ($400) online at retailers like Walmart, Best Buy, GameStop, and Sony's own PlayStation Direct store. Nearly all PlayStation 5 sales are handled online due to the COVID-19 pandemic and overall demand, but some GameStop locations have made consoles available for in-store purchase on occasion. Walmart usually announces PS5 restocks a few hours before consoles are available online. GameStop sends emails to subscribers ahead of PS5 restocks but typically only makes the PS5 available in bundles. Amazon and Newegg have also made PS5 consoles available, though on a less consistent basis. Newegg uses a raffle system to give shoppers a chance to buy rare items like the PS5. We'll keep this post updated as we get more information about PS5 restocks, but ultimately you'll need to keep checking multiple stores and get a bit lucky with timing to secure the console. Where to buy a PS5: stores and price The digital edition of the PlayStation 5 doesn't have a disc drive. Sony Several stores, including Walmart, Amazon, Best Buy, GameStop, Target, and Newegg, have regularly restocked PlayStation 5 consoles since launch, but they typically sell out as soon as they're available online.Sony's PlayStation Direct store has a registration program that functions like a waitlist for a limited supply of PS5 consoles. If selected, shoppers who sign up will receive an email to purchase a PS5 directly from Sony. Registering does not guarantee you'll get an invite, however, and it's not clear how many people will be selected. Invitations to purchase a PS5 will begin to go out to selected shoppers in November 2021.The PlayStation 5 comes in two different models — one that has a 4K Ultra HD Blu-ray drive and a "digital edition" with no disc drive at all. The standard model is priced at $500, and the digital edition is priced at $400.At popular sites for resellers, like eBay and StockX, you can expect to pay between $700 or $800 for the PlayStation 5.You can check the links below to see if the PS5 is currently available at each retailer; we'll update this post if a specific store announces a restock.PlayStation 5 (Standard Edition) PlayStation 5 (Digital Edition) Tips for buying the PS5 A gamer sets up the new Sony Playstation PS5 at his home in Seoul after Sony launched the new console. YELIM LEE/AFP via Getty Images Buying the PlayStation 5 has been a struggle since release, but retailers have been making a steady stream of consoles available. If you have a preferred store, you should look into setting stock alerts with their online tools.Third-party stock-tracking websites like HotStock.io can tell you when a store last had the PlayStation 5 in stock and let you set alerts for multiple retailers. A reseller who made more than $40,000 reselling PS5 consoles last year shared more specific tips on how to find the console online.If you encounter issues while trying to check out with an online retailer, keep trying to refresh the product page to add the console and make sure the PS5 is available and in your cart. If possible, create an account with your preferred retailer and enter your payment and shipping information in advance to help the checkout process move quickly. PlayStation 5 specifications Sony The PlayStation 5 boasts much more powerful hardware than the PlayStation 4 and PS4 Pro. Upgrades include a solid state hard drive and a graphics card capable of ray-tracing technology.For detailed impressions, check out our full PlayStation 5 review.Disc drive: 4K Ultra HD Blu-ray drive (standard edition only)Storage: 825GB M.2 driveHDMI Out: Up to 4K resolution at 120Hz with HDMI 2.1Ports: 1x USB-C, 3x USB 3.1, 1x EthernetCPU: AMD Ryzen Zen 2, 8 cores, 16 threads at 3.5 GHzGPU: AMD Radeon RDNA 2 at 2.23 GHz, 10.3 TFlopsMemory: GDDR6 16GB, 44GB/s bandwidth PlayStation 5 accessories Sony The new PlayStation 5 family of peripherals haven't been nearly as hard to find as the console itself, though they're not of much use without the main course. That said, they do complement the features of the PlayStation 5, so we've taken to the time to explain what they all do.Sony's $70 DualSense controller is a worthy successor to the PS4's popular DualShock, implementing a built-in microphone, haptic feedback for adjustable trigger tension, and advanced rumble features while also improving the battery life and adopting a USB-C charging cable.Wireless Controller for PS5 (small)The $100 Pulse 3D headset is a direct successor to the gold and platinum wireless headsets Sony released for the PlayStation 4. The headset has an adjustable band, built-in microphone, and hardware buttons for mute, voice monitoring, and volume. While the Pulse 3D headset is worth the investment, PS5's 3D audio features will also work with any third-party headset that's been licensed for use on PS4.Pulse 3D Wireless Headset (small)The $30 PlayStation media remote might look appealing, but for $30 you can find a better or cheaper universal remote to control the console. Several smart TV brands also let you control the PS5 with your standard TV remote too, so it's worth giving that a try before making this investment.PlayStation 5 Media Remote (small)The $30 DualSense charging stand can charge two controllers and makes for a nice stand alongside the PS5, but it doesn't actually charge your controllers any faster than using a regular cable.PlayStation 5 DualSense Charging Station (small)The $60 HD camera can be used for streaming in full 1080p and even has a background removal tool, but it cannot be used as a microphone like the PlayStation 4 camera. Luckily, you can just use the DualSense's built-in mic to communicate while playing.PlayStation 5 HD Camera (small) PlayStation 5 exclusive games "Ratchet and Clank: Rift Apart" is Sony's latest PlayStation 5 exclusive. "Ratchet & Clank: Rift Apart" / Sony Sony is committed to creating a full lineup of exclusive games for the PlayStation 5, repeating the same strategy that helped make the PS4 a massive success. Because there are still so many gamers waiting to upgrade to PS5, many of the games released on the new console will also work on PlayStation 4, like "Spider-Man: Miles Morales" and "Sackboy: A Big Adventure."Keep in mind that new games like "Call of Duty Black Ops: Cold War" have been designed to run better on PS5, even if they're available on the PS4. Below, we've listed all the games that require a PlayStation 5 to play, including upcoming titles that don't have release dates yet. Exclusive PS5 games available now"Godfall""Destruction AllStars""Returnal""Astro's Playroom" (pre-installed on PS5)"Ratchet & Clank: A Rift Apart""Final Fantasy VII Remake: Intergrade"Upcoming PS5 exclusive games"Horizon: Forbidden West""God of War: Ragnarok""Gran Turismo 7"For more PlayStation game recommendations, check out our complete roundup of exclusives that make the PS5 worth buying. Read the original article on Business Insider.....»»

Category: topSource: businessinsiderOct 14th, 2021

Biotech Stock Roundup: MRNA"s Vaccine Update, GILD"s CAR T Therapy Label Expansion

Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week. The biotech sector has been in focus last week with important regulatory and pipeline updates. This apart, updates on additional doses of COVID-19 vaccines and antibody treatments continue to grab the limelight.Recap of the Week’s Most Important Stories:Moderna’s Vaccine Update: Moderna MRNA announced that the European Medicines Agency (“EMA”) has authorized a third dose of its COVID-19 vaccine (Spikevax) given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older. Data from a recent double-blind, randomized controlled study among 120 individuals who had undergone solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, or pancreas) showed that a third dose improved immune response compared to placebo in this population. The dose was generally well tolerated.Gilead’s CAR T- Cell Therapy Label Expansion:  Gilead Sciences, Inc.’s GILD Kite announced that it obtained FDA approval for another indication for its CAR T-cell therapy, Tecartus. It has been approved for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).  The approval is based on results from ZUMA-3, a global, multicenter, single-arm, open-label study in which 65% of the evaluable patients (n=54) achieved complete remission (CR) or CR with incomplete hematological recovery (CRi) at a median actual follow-up of 12.3 months.  It is already approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Tecartus is also currently under review in the European Union and the United Kingdom for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.Earlier, Kite submitted a supplemental biologics license Aapplication (sBLA) to the FDA for Yescarta (axicabtagene ciloleucel) to expand its current indication to include the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) in the second-line setting.Regeneron’s Antibody Cocktail Data:  Regeneron Pharmaceuticals, Inc. REGN announced that a phase II/III randomized, double-blind, placebo-controlled study evaluating experimental antibody cocktail, REGEN-COV (casirivimab and imdevimab), in patients hospitalized with COVID-19 met its primary endpoint.The study results showed that REGEN-COV significantly reduced viral load in patients hospitalized with COVID-19 who entered into the trial without having mounted their own antibody response (seronegative) and required low-flow or no supplemental oxygen. REGEN-COV significantly reduced viral load within seven days of treatment.  Patients who received REGEN-COV in this study experienced a 36% reduced risk of dying within 29 days of treatment, and in patients who were seronegative when they entered the trial, the risk was reduced by 56%. The FDA is currently reviewing the request to add treatment in hospital settings to REGEN-COV authorization.Regeneron currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.BioNTech Doses First Patient in Cancer Vaccine Study:  BioNTech SE BNTX announced that it has dosed the first patient in a phase II study of its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457). The open-label phase II study is investigating autogene cevumeran in stage II/III colorectal cancer patients after surgical resection of their tumor and completion of adjuvant chemotherapy. The study has been initiated in the United States, Germany, Spain, and Belgium. It plans to enroll about 200 patients to evaluate the efficacy of BNT122 compared to watchful waiting after surgery and chemotherapy. The primary endpoint for the study is disease-free survival (DFS). Secondary objectives include relapse-free survival (RFS), overall survival (OS) and safety.Separately, BioNTech and partner Pfizer PFE announced that Committee for Medicinal Products for Human Use (“CHMP”) of the EMA issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18???years of age and older.Regulatory Updates From Bristol-Myers: Bristol Myers BMY announced that the EMA has validated its Marketing Authorization Application (MAA) for experimental candidate mavacamten. The MAA is seeking approval for this first-in-class cardiac myosin inhibitor for the treatment of patients with obstructive hypertrophic cardiomyopathy (obstructive HCM). With the validation, EMA’s centralized procedure with CHMP’s assessment begins.The EMA also validated its MAA for the fixed-dose combination of its LAG-3-blocking antibody relatlimab and Opdivo for the first-line treatment of adult and pediatric patients (12 years and older and weighing at least 40 kg) with advanced (unresectable or metastatic) melanoma.PerformanceMedical - Biomedical and Genetics Industry 5YR % Return Medical - Biomedical and Genetics Industry 5YR % ReturnThe Nasdaq Biotechnology Index has lost 3.75% in the past five trading sessions. Among the biotech giants, Moderna has lost 13.56% during the period. Over the past six months, shares of Moderna have soared 155.65%. (See the last biotech stock roundup here: Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More).Image Source: Zacks Investment ResearchWhat's Next in Biotech?Stay tuned for more pipeline and regulatory updates.  Zacks’ Top Picks to Cash in on Artificial Intelligence This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksOct 6th, 2021

Black Friday 2021 lands on November 26 - here"s what to expect, plus early deals you can snag right now

Black Friday is November 26, but retailers are already offering early deals. Here are the best discounts, plus your Black Friday questions, answered. When you buy through our links, Insider may earn an affiliate commission. Learn more. Black Friday 2021 begins November 26. Alyssa Powell/Insider Table of Contents: Masthead StickyFall has arrived, and that means Black Friday 2021 isn't far off. The shopping holiday is set to officially kick off on November 26, and we expect to see a ton of discounts on products across all categories. To help you prepare, we broke down everything you need to know about Black Friday 2021, along with a roundup of some of the best deals you can snag right now.Best deals available right nowAlways Pan (medium, Preferred: Our Place)AirPods Pro (medium, Preferred: Amazon)Galaxy Smart Tag+ (medium, Preferred: Amazon)Studio Buds (medium, Preferred: Amazon)Nomad Leather Sectional (medium, Preferred: Burrow)What is Black Friday?Black Friday is an annual sales event that traditionally happens at the end of November, marking the beginning of the holiday shopping season. The savings event is one of the biggest shopping holidays of the year - sales are so high that the day can push a retailer into "the black," or solvency.Shoppers can expect thousands of deals to crop up during the entire weekend, with tons of solid deals during the lead-up as well.When is Black Friday 2021?Black Friday is always the Friday after Thanksgiving. This year, Black Friday falls on November 26. However, shoppers can expect Black Friday-caliber deals to start popping up in the weeks leading up to the big day.Amazon, as usual, is one of the retailers leading the charge. Its new Epic Deals promotion includes noteworthy discounts on everything from tech to home goods, with new deals dropping every day. It's only October, and we're already seeing some of the best prices of the year on items like AirPods and Beats earbuds. What time does Black Friday start?Technically speaking, Black Friday starts at 12:00 a.m. local time on November 26 for online retailers. However, Black Friday sales start whenever each retailer decides their deals will go live.Judging from what we saw last year, several retailers will be releasing new deals every week leading up to the main event.How long do Black Friday sales last?Don't be fooled by the name that suggests Black Friday is a single day. It's most definitely not. It's more like a shopping season that begins in early November. Black Friday deals started days and weeks in advance of the actual shopping day last year and continued on until a week after Cyber Monday. We expect a similar window of deals this year.What should you buy on Black Friday?Since it falls a few weeks before the gift-giving season, Black Friday provides excellent opportunities to buy and save on all your holiday gifts before the last-minute rush. It's nearly guaranteed that you'll get great value for your money on certain products during Black Friday - but some products tend to see better discounts at other times of the year. If you go in knowing what you're looking for, you're less likely to be ripped off by a fancy-looking coupon or to spend money on products you don't need.Shoppers can expect tons of great deals - including so-called "doorbusters" - online before and early on in Black Friday. During the event, prices will drop to all-time lows, often beating out prices we see over the course of the year. The sale covers every product category: tech, home and kitchen, fashion, and smart home. This Black Friday, shoppers should expect to see similar offers to the ones we saw on Amazon Prime Day, except more wide-ranging.We recommend focusing on the following product categories if you want the best deals: TVsSmart home devicesGaming consoles and video gamesKitchen appliancesHistorically, Black Friday has been a great time to purchase big-ticket electronics - especially larger TVs. Whether you're looking for a top-of-the-line Samsung set or LG OLED, or a budget-friendly TCL or Hisense model, Black Friday will likely deliver several deals.Much like Amazon Prime Day, we saw tons of discounts on smart home products last Black Friday. Amazon Echo products dropped to their lowest prices ever, plus we saw several discounts and bundles on Google's recently released products.This Black Friday we expect to see discounts on the latest Xbox and Playstation console releases, provided they're in stock. While we didn't see any markdowns on the consoles last year, we did see a few bundles crop up and we expect more of them in 2021. If you're looking for a kitchen upgrade, Black Friday is a great time to shop. We saw big discounts on Instant Pot pressure cookers, KitchenAid appliances, pots and pans, plus everything else you'll want for the upcoming holiday season.Of course, the deals found during Black Friday are incredibly wide-ranging. There have also been several deals on diapers, toilet paper, and other household essentials.Is Black Friday or Cyber Monday better?It's complicated, and it matters less every year.For those unfamiliar, Cyber Monday traditionally comes three days after Black Friday, on Monday. However, we've seen Black Friday and Cyber Monday slowly merge and expand to a weeklong, or even a month-long affair. Different products receive better discounts on each day, and the deals that each retailer offers will vary.A good rule of thumb to follow: If you think you see a good deal, (e.g., one we recommend) create the order as soon as possible. While you can always cancel or return a product, it's impossible to take advantage of an inactive, or expired deal.Suppose you purchase a discounted product during Black Friday and see a more significant markdown at another retailer come Cyber Monday. Don't sweat it.You can ask the original storefront to match the price (some automatically refund you the difference), or you can return or cancel the order, then place a new order with a better price. Some orders won't even ship during the weekend, which makes it easy to cancel orders.For those who can shop in-person during Black Friday, we've found that it's better to shop on Black Friday in these situations:For expensive productsFor major storesFor this year's productsWhat stores have Black Friday deals? Outside of a few notable exceptions like REI, nearly every major retailer and direct-to-consumer company is offering markdowns during the event. We've seen deals from Walmart, Best Buy, Dell, Amazon, Adorama, Lowe's, The Home Depot, and more.As we do every Black Friday, we will be sifting through all of the offers and rounding up the best deals from your favorite retailers.Will there be Black Friday shipping delays?Shipping delays and major shopping holidays go hand in hand, and this year is no exception. While we do expect shipping delays, we don't think it will be as bad as last year.When do Black Friday ads come out?Every year, shoppers eagerly await Black Friday advertising to get a sneak peek at the deals each retailer will offer. Shoppers use these "ad scans" to help create their Black Friday game plan. We'll update this section to include all of the available ad scans as soon as they become available.Best Black Friday Deals we saw last yearLast year, we rounded up the best Black Friday tech deals we could find. Some of the best deals we found discounted many products over 50% with hundreds of dollars in savings. Here are some of the best markdowns we saw last year. iRobot Roomba 675 robot vacuum $179 on Amazon, originally $229.LG 75" 80 Series smart webOS TV $999 at Best Buy, originally $1,499.Insignia 24-inch Fire TV $100 from Amazon, originally $170.Lenovo smart clock $35 from Best Buy, originally $80.Samsung 1TB internal SSD $100 from Walmart, originally $280.How we select the best Black Friday dealsWe only choose products that meet our high standard of coverage and that we've either used ourselves or researched carefully.We'll compare the prices among top retailers such as Amazon, Best Buy, Target, and Walmart and include only the deals that are better than all others offered (not including promotional discounts that come from using certain credit cards). All deals will be at least 20% off, with the occasional exception for products that are rarely discounted or provide an outsize value.Read more about how the Insider Reviews team evaluates deals and why you should trust us.Read the original article on Business Insider.....»»

Category: topSource: businessinsiderOct 5th, 2021

Top Stories this AM: Hong Kong pauses trading on Evergrande; a whistleblower"s warnings for Facebook; Fauci says it"s time to "face reality"

Evergrande's Xu Jiayin released a statement on Monday saying that trading was suspended "pending an important announcement from our company about a major transaction." Good morning and welcome to your weekday morning roundup of the top stories you need to know.For more daily and weekly briefings, sign up for our newsletters here.What's going on today: Shares of China Evergrande are suspended on the Hong Kong stock exchange. Shares of its unit Evergrande Property Services Group were also suspended, according to the Hong Kong stock exchange. Chairman Xu Jiayin released a statement on Monday saying that the stocks were suspended "pending an important announcement from our company about a major transaction."Literally the best game of Finders Keepers ever. A woman gets to keep the 4-carat yellow diamond she found at a state park in Arkansas, the only state with a public diamond mine. Staff at Crater of Diamonds State Park identified the diamond, which Noreen Wredberg found within an hour of searching.Fauci says it's time to face facts. Fauci said people blaming immigrants for COVID-19 spread in the US need to "face reality." A recent poll found 55% of Republicans believed immigrants and tourists bringing in COVID-19 was a major reason for the latest surgeYeah, good luck with that. Trump is demanding that the Pulitzer Prize committee strip NYT and WaPo journalists of their awards for reporting on Russian interference in the 2016 presidential election. The Washington Post and The New York Times were awarded Pulitzers in 2018 for their coverage of Russian interference in the 2016 election.Facebook's failures exposed. Whistleblower Frances Haugen says a Facebook study found only up to 5% of hate on the platform is addressed. The copied documents also showed that only .6% of violence and incitement on the platform was addressed. In the same interview, Haugen said she quit after seeing internal Facebook research that showed its Instagram platform contributes to eating disorders and suicidal thoughts in teenage girls.That's all for now. See you tomorrow. Read the original article on Business Insider.....»»

Category: topSource: businessinsiderOct 4th, 2021

Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More

Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta. In a rather active week for large-drug companies, Merck MRK announced that it plans to buy Acceleron Pharma for about $11.5 billion. The FDA approved AbbVie’s ABBV new migraine drug, Qulipta.  AstraZeneca AZN exercised its option to buy the full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs. Sanofi SNY ended the development of its mRNA-based COVID vaccine.Recap of the Week’s Most Important StoriesMerck to Buy Acceleron For $11.5B: Merck announced a definitive agreement to acquire Acceleron Pharma for $180 per share in cash or an approximate total equity value of $11.5 billion. The deal, if successful, will add Acceleron’s promising phase III pipeline candidate, sotatercept, which is being evaluated for the treatment of pulmonary arterial hypertension. This apart, Acceleron earns royalties on sales of Reblozyl, which has been developed as part of its global collaboration with Bristol Myers. Reblozyl is approved for the treatment of anemia in certain blood disorders. The transaction is expected to be closed in the fourth quarter of 2021.Merck’s phase III KEYNOTE-394 study on Keytruda in patients with advanced hepatocellular carcinoma previously treated with Bayer’s Nexavar (sorafenib) met its primary endpoint of overall survival (OS). The data showed that Keytruda plus best supportive care led to a statistically significant improvement in OS versus placebo plus best supportive care. The study also showed statistically significant improvements for Keytruda for the secondary endpoints of progression-free survival (PFS) and objective response rate (ORR) compared to placebo.FDA Approves AbbVie’s New Migraine Drug: The FDA approved AbbVie’s atogepant for preventive treatment of episodic migraine in adults. The drug will be marketed as Qulipta. The regulatory application for Qulipta was based on data from a robust clinical program, which included data from the phase III ADVANCE study, a pivotal phase IIb/III study and the phase III long-term safety study. Qulipta will be available in the United States from early next month.Pfizer Begins New Studies for COVID Prevention, mRNA Flu Vaccine: A phase II/III study (EPIC-PEP) was initiated by Pfizer to evaluate its investigational, novel oral antiviral, PF-07321332 in combination with a low dose of ritonavir for the prevention of COVID-19 infection. PF-07321332 is already being evaluated in separate phase II/III studies, one in SARS-CoV-2 infected patients who are at high risk of severe illness (including hospitalization or death) and another in infected patients who are at standard risk.Pfizer also announced that the first participants have been dosed in a phase I study to evaluate a single dose quadrivalent mRNA influenza vaccine in healthy adults. Pfizer plans to explore the mRNA technology in respiratory viruses other than influenza and also eventually aims to expand to develop the mRNA technology in oncology and genetic diseases.The FDA delayed its decision on Pfizer and OPKO Health’s biologics license application (“BLA”) for growth hormone deficiency (“GHD”) candidate somatrogon by three months. The FDA’s decision is now expected in January 2022.Pfizer submitted the initial data from a pivotal phase II/III study on its COVID-19 vaccine in children 5 to less than 12 years of age. Top-line data from the study were announced earlier this month. A formal filing seeking Emergency Use Authorization (EUA) for use in children of this age group is expected to be filed soon.Sanofi Dumps mRNA COVID Vaccine Candidate: Sanofi said it is dropping plans of development of its mRNA-based COVID vaccine (which it acquired as a part of its recent acquisition of Translate Bio) after the success of Pfizer/BioNTech and Moderna in this field. The decision to drop mRNA COVID vaccine development came despite positive phase I/II study interim results. Interim data from Sanofi’s phase I/II study of its mRNA-based vaccine candidate showed neutralizing antibody seroconversion in 91% to 100% of study participants, two weeks after the second dose was given across the three dosages tested. The positive data has encouraged the company to develop a modified quadrivalent mRNA-based flu vaccine, for which it targets to initiate clinical studies in 2022.However, Sanofi continues to develop its adjuvanted recombinant protein candidate vaccine, in partnership with Glaxo, which is in phase III studies.AstraZeneca to Fully Acquire Caelum Biosciences: AstraZeneca’s newly acquired subsidiary, Alexion has exercised its option to acquire all remaining shares of Caelum Biosciences in which it holds a minority equity interest. With the full acquisition of Caelum, AstraZeneca will add the latter’s phase III candidate, CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody for the treatment of light chain amyloidosis.FDA’s Priority Tag for Glaxo Cabotegravir Long-Acting for PrEP: The FDA granted priority review to Glaxo’s GSK new drug application seeking approval for its long-acting cabotegravir for prevention of HIV also called pre-exposure prophylaxis or PrEP. The FDA’s decision is expected on Jan 24, 2022. The NDA filing was based on data from two phase IIb/III studies, HPTN 083 and HPTN 084. Regulatory applications in other countries will be filed by the end of 2021. The long-acting injectable regimen of cabotegravir is approved in combination with J&J’s Edurant (rilpivirine), as Cabenuva, for the treatment of HIV-1 infection in virologically suppressed adultsGlaxo’s HIV subsidiary, ViiV Healthcare, announced that it is in-licensing rights to a third integrase inhibitor, S-365598 from Shionogi for an upfront payment of £20 million. S-365598, a pre-clinical candidate, has shown potential for use in ultra-long-acting HIV regimens (regimens that can be taken with infrequent dosing of every three months or longer.). Clinical studies on S-365598 are expected to begin by 2023.FDA Grants Expanded Use of Lilly’s Erbitux: The FDA approved Lilly’s LLY drug Erbitux in combination with Pfizer’s Braftovi (encorafenib) for metastatic colorectal cancer with a BRAF V600E mutation. Pfizer’s Braftovi had received approval from the FDA for the same indication in April 2020 in combination with Erbiux. The FDA approval for Erbitux+ Braftovi for the above indication was based on data from Pfizer’s phase III BEACON CRC study.Lilly also said that it will lower the list price of its non-branded insulin, the Insulin Lispro injection, from Jan 1, 2022, by an additional 40% in the United States. The new list price will be 70% less than the counterparts of Lispro’s injection Humalog U-100.J&J’s Xarelto Betters Aspirin in Pediatric Fontan Procedure Study: J&J JNJ announced data from a phase III study, which showed that an oral suspension formulation of its medicine, Xarelto led to numerically fewer blood clots and clinical events associated with blood clots compared to aspirin in pediatric patients with congenital heart disease who have undergone the Fontan procedure.J&J also initiated a phase III study (EVERGREEN) on its investigational RSV vaccine candidate in adults ages 60 years or older. The study, which was initiated based on positive data from the phase IIb CYPRESS study, is expected to enroll approximately 23,000 participants 60 years and older.The NYSE ARCA Pharmaceutical Index declined 1.9% in the last five trading sessions.Large Cap Pharmaceuticals Industry 5YR % Return Large Cap Pharmaceuticals Industry 5YR % ReturnHere’s how the eight major stocks performed in the last five trading sessions.Image Source: Zacks Investment ResearchIn the last five trading sessions, Merck gained the highest (2.1%) while Pfizer declined the most (2.7%)In the past six months, Lilly recorded the maximum gain (24.7%) while Novartis declined the most (5%)(See the last pharma stock roundup here: PFE Booster Jab Gets FDA Nod, JNJ’s New Data on COVID-19 Shot)What's Next in the Pharma World?Watch out for regular pipeline and regulatory updates next week. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksOct 1st, 2021

"It Really Is THAT Good" - Wall Street Reacts To Merck"s "Big Deal" Drug

"It Really Is THAT Good" - Wall Street Reacts To Merck's "Big Deal" Drug As we reported earlier this morning, Merck has released what experts say are "extremely positive" test results for a COVID anti-viral that cuts risk of hospitalization in half, while also dramatically reducing the risk of death. The data were so profoundly positive that an oversight board ended the trial, claiming that withholding the drug from patients in the placebo group would be "unethical". Merck says it can deliver 10MM doses of the new drug, called Molnupiravir, by the end of the year, by which it should be approved by the FDA and possibly foreign regulators as well (the wheels of bureaucracy are reportedly turning as quickly as they can).  Merck is submitting an emergency application for authorization of the drug, and we may see it in use during the next two weeks. The regiment is 2 pills a day for 5 days, and it's most helpful within 5 days of infection. The news has sent US stocks into the green for the day, while shares of Merck briefly soared as much as 12%. Meanwhile, shares of Moderna are really taking it on the chin, and have fallen by more than 10%. After failing to foresee the potential "game-changing" impact of the new drug, Wall Street analysts are scrambling to interpret what Molnupiravir will mean for markets and the economy. In a roundup of commentary from Bloomberg, most agreed that the drug would be a "game-changer" for the pandemic, and that it will likely receive emergency use authorization before the end of the year. Evercore ISI analyst Umer Raffat referred to the pill as a game changer for Covid-19, writing that the data “really is THAT good". Expects oral pills to be a "big deal" in combating Covid with the ease of use and scale of manufacturing being a game changer From MRK stock perspective, pipeline should finally start to get real credit – starting with this readout today" Barclays analyst Carter Gould expects a straightforward regulatory decision for the pill to receive emergency use authorization from the FDA with the data representing a needed win for Merck in combating Covid-19. Highlights that the Street had estimated near-zero value for the drug prior to today’s news with Merck set up well to book a $1.2 billion contract later this year. Cantor analyst Louise Chen highlighted that the data showed consistent efficacy across Gamma, Delta, and Mu variants and said the pill could "change the treatment paradigm" "Positive data could clear path to take a slice of an untapped pie in the COVID treatment landscape (multi-blockbuster opportunity in the U.S. alone)" SVB Leerink analyst Daina Graybosch wrote that the drug could unlock more than $10b in near-term orders and also “represent the best option for bringing the pandemic under control worldwide". Expects approval in the U.S. before year-end with additional supply contracts in the coming weeks Morgan Stanley’s Matthew Harrison wrote that the data are a significant positive for patients and the broader public’s risk perception as it relates to COVID * * * Source: Bloomberg Tyler Durden Fri, 10/01/2021 - 12:40.....»»

Category: personnelSource: nytOct 1st, 2021

Where to buy a PlayStation 5 - GameStop will sell PS5 bundles in select stores on September 30

The PlayStation 5 continues to be in high demand, but we've got the latest details on restocks and tips for finding the console online and in stores. When you buy through our links, Insider may earn an affiliate commission. Learn more. Sony's PlayStation 5 remains hard to find months after its release. Sony Sony's PlayStation 5 launched with two models- the $500 standard PS5 and a $400 digital edition. The PS5 remains difficult to find, but retailers like Best Buy and GameStop restock regularly. For detailed thoughts on the PS5's performance, check out our full PlayStation 5 review. Table of Contents: Masthead StickyPlayStation 5 (small)Playstation 5 (All-Digital) (small)The PlayStation 5 is Sony's fastest-selling video game console ever, with more than 10 million systems sold since its launch in November 2020. However, the record demand and an international chip shortage have made the PS5 one of the hardest items to buy in stores or online.The high demand for PS5 also makes it a target for resellers, many of whom use automated tools to purchase consoles online as soon as they're available. Sony acknowledged the supply challenges in a July 2021 statement, but it remains unclear when the console will become readily available.We've seen weekly restocks of the PS5 ($500) and PS5 Digital Edition ($400) online at retailers like Walmart, Best Buy, GameStop, and Sony's own PlayStation Direct store. Nearly all PlayStation 5 sales are handled online due to the COVID-19 pandemic and overall demand, but some GameStop locations have made consoles available for in-store purchase on occasion.GameStop locations near Atlanta, New York City, and the Dallas-Fort Worth area of Texas will be offering PlayStation 5 bundles in-store on September 30. It's not clear exactly what each bundle will include or how much they will cost. You can visit GameStop's website to check if your area has participating stores.Walmart usually announces PS5 restocks a few hours before consoles are available online. GameStop sends emails to subscribers ahead of PS5 restocks but typically only makes the PS5 available in bundles. Amazon and Newegg have also made PS5 consoles available, though on a less consistent basis. Newegg uses a raffle system to give shoppers a chance to buy rare items like the PS5. We'll keep this post updated as we get more information about PS5 restocks, but ultimately you'll need to keep checking multiple stores and get a bit lucky with timing to secure the console. Where to buy a PS5: stores and price The digital edition of the PlayStation 5 doesn't have a disc drive. Sony Several stores, including Walmart, Amazon, Best Buy, GameStop, Target, and Newegg, have regularly restocked PlayStation 5 consoles since launch, but they typically sell out as soon as they're available online.Some GameStops have had consoles for sale in-store, but availability depends on when they're shipped. GameStop stores in the Atlanta, New York City, and Dallas-Fort Worth areas will have PlayStation 5 bundles in stock on September 30. You can check the GameStop website to see if your local store is participating.The PlayStation 5 comes in two different models — one that has a 4K Ultra HD Blu-ray drive and a "digital edition" with no disc drive at all. The standard model is priced at $500, and the digital edition is priced at $400.At popular sites for resellers, like eBay and StockX, you can expect to pay between $700 or $800 for the PlayStation 5.You can check the links below to see if the PS5 is currently available at each retailer; we'll update this post if a specific store announces a restock.PlayStation 5 (Standard Edition) PlayStation 5 (Digital Edition) Tips for buying the PS5 A gamer sets up the new Sony Playstation PS5 at his home in Seoul after Sony launched the new console. YELIM LEE/AFP via Getty Images Buying the PlayStation 5 has been a struggle since release, but retailers have been making a steady stream of consoles available. If you have a preferred store, you should look into setting stock alerts with their online tools.Third-party stock-tracking websites like HotStock.io can tell you when a store last had the PlayStation 5 in stock and let you set alerts for multiple retailers. A reseller who made more than $40,000 reselling PS5 consoles last year shared more specific tips on how to find the console online.If you encounter issues while trying to check out with an online retailer, keep trying to refresh the product page to add the console and make sure the PS5 is available and in your cart. If possible, create an account with your preferred retailer and enter your payment and shipping information in advance to help the checkout process move quickly. PlayStation 5 specifications Sony The PlayStation 5 boasts much more powerful hardware than the PlayStation 4 and PS4 Pro. Upgrades include a solid state hard drive and a graphics card capable of ray-tracing technology.For detailed impressions, check out our full PlayStation 5 review.Disc drive: 4K Ultra HD Blu-ray drive (standard edition only)Storage: 825GB M.2 driveHDMI Out: Up to 4K resolution at 120Hz with HDMI 2.1Ports: 1x USB-C, 3x USB 3.1, 1x EthernetCPU: AMD Ryzen Zen 2, 8 cores, 16 threads at 3.5 GHzGPU: AMD Radeon RDNA 2 at 2.23 GHz, 10.3 TFlopsMemory: GDDR6 16GB, 44GB/s bandwidth PlayStation 5 accessories Sony The new PlayStation 5 family of peripherals haven't been nearly as hard to find as the console itself, though they're not of much use without the main course. That said, they do complement the features of the PlayStation 5, so we've taken to the time to explain what they all do.Sony's $70 DualSense controller is a worthy successor to the PS4's popular DualShock, implementing a built-in microphone, haptic feedback for adjustable trigger tension, and advanced rumble features while also improving the battery life and adopting a USB-C charging cable.Wireless Controller for PS5 (small)The $100 Pulse 3D headset is a direct successor to the gold and platinum wireless headsets Sony released for the PlayStation 4. The headset has an adjustable band, built-in microphone, and hardware buttons for mute, voice monitoring, and volume. While the Pulse 3D headset is worth the investment, PS5's 3D audio features will also work with any third-party headset that's been licensed for use on PS4.Pulse 3D Wireless Headset (small)The $30 PlayStation media remote might look appealing, but for $30 you can find a better or cheaper universal remote to control the console. Several smart TV brands also let you control the PS5 with your standard TV remote too, so it's worth giving that a try before making this investment.PlayStation 5 Media Remote (small)The $30 DualSense charging stand can charge two controllers and makes for a nice stand alongside the PS5, but it doesn't actually charge your controllers any faster than using a regular cable.PlayStation 5 DualSense Charging Station (small)The $60 HD camera can be used for streaming in full 1080p and even has a background removal tool, but it cannot be used as a microphone like the PlayStation 4 camera. Luckily, you can just use the DualSense's built-in mic to communicate while playing.PlayStation 5 HD Camera (small) PlayStation 5 exclusive games "Ratchet and Clank: Rift Apart" is Sony's latest PlayStation 5 exclusive. "Ratchet & Clank: Rift Apart" / Sony Sony is committed to creating a full lineup of exclusive games for the PlayStation 5, repeating the same strategy that helped make the PS4 a massive success. Because there are still so many gamers waiting to upgrade to PS5, many of the games released on the new console will also work on PlayStation 4, like "Spider-Man: Miles Morales" and "Sackboy: A Big Adventure."Keep in mind that new games like "Call of Duty Black Ops: Cold War" have been designed to run better on PS5, even if they're available on the PS4. Below, we've listed all the games that require a PlayStation 5 to play, including upcoming titles that don't have release dates yet. Exclusive PS5 games available now"Godfall""Destruction AllStars""Returnal""Astro's Playroom" (pre-installed on PS5)"Ratchet & Clank: A Rift Apart""Final Fantasy VII Remake: Intergrade"Upcoming PS5 exclusive games"Horizon: Forbidden West""God of War: Ragnarok""Gran Turismo 7"For more PlayStation game recommendations, check out our complete roundup of exclusives that make the PS5 worth buying. Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 29th, 2021

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week. It has been a busy week for the biotech sector with loads of regulatory and pipeline updates. Acquisitions are back in full swing in the sector. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the contagion.Recap of the Week’s Most Important Stories:Acceleron Up on Rumors of Takeover: Shares of Acceleron Pharma Inc. XLRN have jumped significantly since Friday on rumors of a potential takeover by a pharma giant.  Per a Bloomberg report, the company is in advanced discussions to be acquired by a pharma/biotech bigwig for $11 billion or $180 per share. Acceleron’s promising pipeline candidate — sotatercept — which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), is most likely the key attractive point for the companies interested. Acceleron is executing on its phase III development of the same following positive results from the phase II study, PULSAR. The candidate is being developed in collaboration with Bristol Myers.  This apart, the company earns royalties on sales of Reblozyl (luspatercept-aamt), which has been developed as part of its global collaboration with Bristol Myers.  Reblozyl is approved for the treatment of anemia in certain blood disorders. The PAH space represents potential and hence Acceleron is likely to be in the spotlight. Biogen, Eisai Submit Application for AD Drug: Biogen BIIB and partner Eisai announced that the latter has initiated a rolling submission of a biologics license application (BLA) for pipeline candidate, lecanemab (BAN2401).  The BLA is seeking approval for the candidate as a treatment for early Alzheimer’s disease (AD) under an accelerated pathway in the United States. Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody. The BLA is primarily supported by clinical, biomarker, and safety data from a phase IIb study evaluating lecanemab in patients with early AD and confirmed amyloid pathology. Data from the study has shown that treatment with the candidate led to a high degree of decline in amyloid beta plaque, a key criterion for the measurement of disease improvement in AD patients. The study data also showed that treatment with lecanemab resulted in a consistent reduction of clinical decline across several clinical endpoints.Regulatory Update on Amgen’s Repatha : Amgen AMGN announced that the FDA has approved Repatha (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C. The approval was based on encouraging data from the phase IIIb HAUSER-RCT evaluating the safety and efficacy of Repatha in pediatric patients. Data showed that monthly treatment with Repatha reduced LDL-C by mean 38% from baseline compared to placebo, meeting its primary endpoint. Repatha also received the FDA approval as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients. Repatha was already approved for treating HoFH patients aged 13 and older and is now available as a treatment for patients aged 10 and older.Pipeline Update From Biohaven: Biohaven Pharmaceutical BHVN announced that its pipeline candidate verdiperstat did not meet the primary and secondary endpoints in a late-stage study in multiple system atrophy (MSA). Verdiperstat is an investigational first-in-class, potent, selective, brain-penetrant, and irreversible myeloperoxidase (MPO) enzyme inhibitor that Biohaven is developing for the treatment of neurodegenerative diseases.  Results from the phase III study showed that verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy measure, nor on the key secondary efficacy measures.Update on Novavax Vaccine: Novavax NVAX and partner Serum Institute of India Pvt. Ltd. announced a regulatory submission to the World Health Organization (“WHO”) for emergency use listing (EUL) of Novavax's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant, NVX-CoV2373. Shares surged on the news. NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2. Novavax and Serum Institute have completed the submission of modules required by regulatory agencies in India, Indonesia, and the Philippines for the initiation of a review of the vaccine, including preclinical, clinical, and chemistry, manufacturing, and controls data. The submission to WHO is based on the companies' regulatory submission to the Drugs Controller General of India.  The listing, if allowed, will enable the company to supply its COVID-19 vaccine to nations participating in the COVAX facility. The COVAX facility aims to provide equitable access to COVID-19 vaccines across low- and lower-middle-income countries.Incyte Collaborates With Syndax: Incyte INCY announced a worldwide collaboration and license agreement with Syndax Pharmaceuticals, Inc. to develop and commercialize the latter’s axatilimab, an anti-CSF-1R monoclonal antibody. The two companies plan to expand the development of axatilimab in chronic graft-versus-host disease (cGVHD) with additional monotherapy and combination trials planned in 2022.  Per the terms, Incyte will lead global commercial activities for axatilimab across all indications. Both the companies will share profits equally in the United States and Syndax will receive double-digit royalties on sales outside the country. Syndax will retain the option to co-promote axatilimab for any approved indications in the United States. In exchange, Syndax will receive an upfront payment of $117 million and a $35 million equity investment, which will be purchased at $24.62 per share, a 30% premium to the volume-weighted average price over the 10 days prior to Sep 24, 2021. Syndax is also entitled to receive up to an additional $450 million in milestone payments.Incyte currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.PerformanceMedical - Biomedical and Genetics Industry 5YR % Return Medical - Biomedical and Genetics Industry 5YR % ReturnThe Nasdaq Biotechnology Index has lost 4.32% in the past five trading sessions. Among the biotech giants, Moderna has lost 11.48% during the period. Over the past six months, shares of Moderna have soared 211.3%. (See the last biotech stock roundup here: Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA).Image Source: Zacks Investment ResearchWhat's Next in Biotech?Stay tuned for more pipeline and regulatory updates.  Zacks' Top Picks to Cash in on Artificial Intelligence In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Novavax, Inc. (NVAX): Free Stock Analysis Report Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report Biohaven Pharmaceutical Holding Company Ltd. (BHVN): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 29th, 2021

Top Stories this AM: Stocks rise despite energy crunch, Evergrande; how to make money mining bitcoin - from home; Musk goes nuclear

US stock futures rose on Wednesday, pointing to a rebound at the open after equities suffered their biggest fall since May the previous day. Good morning and welcome to your weekday morning roundup of the top stories you need to know.For more daily and weekly briefings, sign up for our newsletters here.What's going on today: US futures point to stock market rebound after biggest drop since May, but global energy crunch fans fears of inflation. US stocks looked set to climb at the open, but an energy crunch, the US debt ceiling, and China's Evergrande gave investors plenty to think about.The wonders of Weibo. Chinese stock market influencers are helping to quell Evergrande-related protests by pushing positive messages about the company's future. An expert told Insider that these messages might be helping to pacify smaller investors who are less in-the-know about Evergrande.Prank problems. A prominent anti-vaxxer gave out his phone number at a rally claiming "he has nothing to hide." Two days later, he's begging people to stop calling him. Chris Saccoccia, known by the pseudonym Chris Sky, said he's received thousands of calls since giving his phone number out at the rally. Musk goes nuclear. Elon Musk says he's "pro-nuclear" power and is "surprised by some of the public sentiment" against it. Musk pointed to Germany's nuclear power plant phase out, which forced the country to rely on dirtier coal plants. Soccer flop. Beleaguered real-estate giant Evergrande's $1.8 billion lotus-shaped soccer stadium is partially built and in shambles amid the company's impending collapse. The stadium was touted in its 2020 groundbreaking ceremony to have a seating capacity of 100,000, to rival FC Barcelona's Camp Nou.Workin' in the 'coin mines. The CEO of Compass Mining breaks down why bitcoin is 'incredibly profitable' to mine right now - and shares how retail investors can mine the largest cryptocurrency at home. "You really only have four inputs. You've got the cost of your hardware, your monthly expenses, your cost of power, and the price of bitcoin, that's it," CEO Whit Gibbs explained. "If you can line those four metrics up properly, then the economics will work for you."That's all for now. See you tomorrow. Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 29th, 2021

Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ"s New Data on COVID-19 Shot

FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine. This week was all about booster doses of COVID-19 vaccines. The FDA granted emergency use approval (EUA) to Pfizer PFE/BioNTech’s BNTX COVID-19 vaccine booster shots for older adults and high-risk people. J&J’s JNJ new data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. Recap of the Week’s Most Important StoriesFDA Approves Pfizer’s COVID-19 Booster for Older Adults and High-Risk Groups: The FDA granted EUA to a booster dose of Pfizer/BioNTech’s mRNA-based COVID-19 vaccine, Comirnaty, for individuals 65 years and older and also those in high-risk groups. However, the FDA did not approve the booster dose for the entire population (people 16 years of age and older) for which Pfizer/BioNTech were seeking approval.The FDA’s decision was more or less in line with the recommendation issued by its Vaccines and Related Biological Products Advisory Committee (“VRBPAC”) last week. The VRBPAC voted unanimously, recommending that the FDA grant EUA to Comirnaty booster dose for individuals 65 years and older and those at high risk of severe COVID-19. However, the panel voted against approving the booster for the general population.Pfizer’s pivotal phase II/III study showed that its COVID-19 vaccine was safe, well-tolerated, and initiated robust neutralizing antibody responses in children five to 11 years of age. The companies plan to submit the data to the FDA and other regulators soon.Pfizer/BioNTech announced plans to provide the U.S. government with 500 million additional doses of Comirnaty at not-for-profit price for donation to poorest countries. With the latest deal, the total number of vaccine doses to be supplied to the U.S. government for donation by Pfizer/BioNTech adds up to 1 billion.J&J’s Promising COVID-19 Booster Data: J&J presented additional data from the phase III ENSEMBLE study, which showed that a booster dose given 56 days after the first jab led to 94% protection against mild to severe COVID-19 in the United States. The data also demonstrated that when the booster jab was given two months after the first shot, antibody levels were four to six times higher than observed after the first vaccination. Also, antibody levels increased nine-fold one week after the booster dose, when the same was given six months after the first shot. J&J also said that the phase III data together with real-world evidence confirmed its vaccine’s strong and long-lasting protection against COVID-19-related hospitalizations and death, even after a single shot.AstraZeneca’s Key Cancer Data at ESMO: AstraZeneca AZN presented detailed data from the head-to-head DESTINY-Breast03 phase III study on Enhertu at the European Society for Medical Oncology (ESMO) Congress. The data showed that Enhertu reduced the risk of death or tumor progression by 72% in patients with HER2-positive metastatic breast cancer previously treated with Roche’s Kadcyla (trastuzumab emtansine (T-DM1)) and a taxane. At ESMO, AstraZeneca also presented three-year data from the CASPIAN phase III study on its PD-L1 inhibitor, Imfinzi. The data showed that Imfinzi plus chemotherapy tripled patient survival at three years in first-line extensive-stage small cell lung cancer.AstraZeneca signed a new collaboration with VaxEquity, an Imperial College London spin-off, to discover and develop self-amplifying next generation RNA therapeutics leveraging VaxEquity’s saRNA platform.AbbVie Seeks Approval for Skyrizi in Crohn’s Disease: AbbVie ABBV submitted regulatory application in the United States seeking approval for its new drug Skyrizi (risankizumab) as a potential treatment for moderate to severe Crohn’s disease (“CD”) both as a 600mg intravenous (“IV”) induction and 360mg subcutaneous (“SC”) maintenance therapy. The filing is supported by data from three phase III studies – ADVANCE, MOTIVATE and FORTIFY – which evaluated the safety and efficacy of Skyrizi in CD patients. Skyrizi is presently approved to treat moderate to severe plaque psoriasis.EU Signs Joint Procurement Deal for Lilly’s COVID-19 Cocktail Drug: Eli Lilly LLY signed a joint procurement agreement with the European Commission to supply 220,000 doses of its cocktail antibody medicine, bamlanivimab plus etesevimab together, for treating confirmed COVID-19. The agreement will allow participating European countries to purchase the cocktail drug directly from Lilly once the medicine is authorized by European regulatory authorities. The cocktail medicine is under review by the European Medicines Agency (“EMA”). In March, the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had given a position opinion recommending approval of bamlanivimab and etesevimab together as a treatment for COVID-19 in patients aged 12 and older.Novartis’ New Acquisition: Novartis NVS acquired Arctos Medical, which expanded its optogenetics portfolio by adding the latter’s pre-clinical optogenetics-based AAV gene therapy program. The acquisition is in line with Novartis’ goal to make optogenetics-based therapies to restore vision to patients with advanced blindness.Novartis announced a collaboration with SOLTI Innovative Cancer Research (SOLTI) to conduct HARMONIA study. HARMONIA is a phase III, head-to-head study evaluating Kisqali versus Pfizer’s Ibrance in patients with HR+/HER2- advanced breast cancer. The study aims to identify the best drug between Kisqali and Ibrance for patients with aggressive HER2-enriched intrinsic subtype of HR+/HER2- advanced breast cancer (ABC). Enrolment in the study is expected to begin in the first quarter of 2022.The NYSE ARCA Pharmaceutical Index rose 0.2% in the last five trading sessions. Large Cap Pharmaceuticals Industry 5YR % Return Large Cap Pharmaceuticals Industry 5YR % Return Here’s how the eight major stocks performed in the last five trading sessions. Image Source: Zacks Investment Research In the last five trading sessions, AstraZeneca gained the highest (5.1%) while Novartis declined the most (1.0%)In the past six months, Lilly recorded the maximum gain (26.8%) while Novartis declined the most (4.2%)(See the last pharma stock roundup here: ABBV’s Deal With RGNX, LLY COVID Drug’s Government Order Win)What's Next in the Pharma World?Watch out for regular pipeline and regulatory updates next week. Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 24th, 2021

Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week. It has been a busy week for the biotech sector with quite a few drug approvals. Regulatory and pipeline updates from bigwigs like Biogen BIIB and Bristol Myers BMY, among others, have also grabbed the spotlight.Recap of the Week’s Most Important Stories:Regulatory and Pipeline Updates From Biogen: Biogen announced that the FDA approved Byooviz, a biosimilar referencing ophthalmology drug Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). The biosimilar has been developed in collaboration with Samsung Bioepis Co., Ltd. Per the company, this is the first ophthalmology biosimilar approved in the United States.  It was approved in Europe in August.Earlier, the Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion and recommended granting marketing authorization to Vumerity (diroximel fumarate) in the European Union for the treatment of adults with relapsing-remitting multiple sclerosis. A final decision on the same is expected in the coming months.Biogen also announced top-line results from its phase II CONVEY study on pipeline candidate vixotrigine (BIIB074). The candidate is a non-opioid investigational oral pain drug being evaluated for the treatment of small fiber neuropathy (SFN). The study was a phase II placebo-controlled, double-blind, enriched enrollment randomized withdrawal study that enrolled 265 patients to evaluate the efficacy and safety of vixotrigine in treating pain experienced by participants with confirmed SFN that is idiopathic or associated with diabetes mellitus.  After a 4-week open-label run-in period, 123 responders to vixotrigine were randomized to receive either 200 mg or 350 mg vixotrigine or placebo twice-daily for 12 weeks in the double-blind portion of the study. The 200 mg dose achieved the primary endpoint of a statistically significant reduction in the mean average daily pain score versus placebo during the treatment period. However, the 350 mg arm failed to meet the primary endpoint. Nonetheless, the 350 mg dosage did achieve a statistically significant increase in the Patient Global Impression of Change at week 12, which is a measure of patients’ overall improvement when compared to baseline.Incyte Wins FDA Nod for AD Treatment:  Incyte INCY announced that the FDA has approved the cream formulation of its selective JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis (AD).  Ruxolitinib cream has been approved under the brand name Opzelura for the short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.  The approval makes Opzelura, the first and only topical formulation of a JAK inhibitor, approved in the United States. The FDA approval was based on data from the TRuE-AD (Topical Ruxolitinib Evaluation in Atopic Dermatitis) clinical trial program, consisting of two randomized, double-blind, vehicle-controlled phase III studies (TRuE-AD1 and TRuE-AD 2).Incyte currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Updates From Bristol Myers:  Bristol Myers Squibb announced that the FDA has accepted its biologics license application (BLA) for the fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno-oncology Opdivo, administered as a single infusion, for the treatment of adult and pediatric patients (12 years and older and weighing at least 40 kg) with unresectable or metastatic melanoma. The agency has granted Priority Review to the application and set a target action date of Mar 19, 2022.  The submitted BLA was based on the positive efficacy and safety results of phase II/III RELATIVITY-047 study.Earlier, the CHMP recommended approval of Opdivo in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.Exelixis’ Cabometyx Label Expansion: Exelixis EXEL announced that the FDA approved Cabometyx (cabozantinib) for yet another indication. The drug is now approved in the United States for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy. The patients are also radioactive iodine-refractory or ineligible. The FDA approval was based on positive results from the phase III study, COSMIC-311, which demonstrated significant improvement in progression-free survival with Cabometyx versus placebo.  The drug is already approved in the United States for advanced renal cell carcinoma and hepatocellular carcinoma.Setback for Verrica:  Verrica Pharmaceuticals VRCA suffered a setback with the FDA issuing a Complete Response Letter (CRL) to its new drug application (NDA) for the lead product candidate, VP-102.  The NDA is seeking approval of the candidate for the treatment of molluscum contagiosum (molluscum), a highly contagious viral skin disease.The CRL was issued as the regulatory body has identified deficiencies at a facility of a contract manufacturing organization (CMO) that are not specifically related to the manufacturing of VP-102 but instead raise general quality issues at the facility. Nevertheless, the agency did not identify any clinical, safety or product-specific Chemistry, Manufacturing, and Controls (CMC) deficiencies related to VP-102. Per the company, the CMO implemented corrective actions to address the agency’s concerns and it expects a satisfactory resolution of the facility's identified deficiencies from the FDA within the next 30 business days. Meanwhile, Verrica will engage with the FDA to demonstrate that its good manufacturing practices, controls, and processes ensure that any deficiencies at the CMO do not affect the efficacy, safety or quality of VP-102.Seagen Wins Drug Approval: Seagen Inc. SGEN and partner Genmab A/S announced that the FDA has granted accelerated approval to Tivdak (tisotumab vedotin-tftv) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The accelerated approval was based on tumor response and the durability of the response. Continued approval for the same may be contingent upon verification and description of clinical benefit in confirmatory trials. The BLA for Tivdak was submitted in February 2021 and accepted with priority review in April 2021. The submission was based on the results of the innovaTV 204 study.PerformanceMedical - Biomedical and Genetics Industry 5YR % Return  Medical - Biomedical and Genetics Industry 5YR % ReturnThe Nasdaq Biotechnology Index has gained 0.83% in the past five trading sessions. Among the biotech giants, Incyte has gained 5.29% during the period. Over the past six months, shares of Moderna have soared 198.1%. (See the last biotech stock roundup here: Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More).Image Source: Zacks Investment ResearchWhat's Next in Biotech?Stay tuned for more pipeline and regulatory updates.  Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Seagen Inc. (SGEN): Free Stock Analysis Report Verrica Pharmaceuticals Inc. (VRCA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 22nd, 2021

How to navigate GameStop madness - The strategy that outsmarted Wall Street - How Reddit traders are driving a populist movement

Reddit day traders turned the stock market on its ear last week by pumping stocks like GameStop to the moon. Here's everything you need to know. Hello everyone! Welcome to this weekly roundup of Investin.....»»

Category: dealsSource: nytJan 31st, 2021

SFBT Digest: S.F."s school-name revolution, Reddit stock tips and other things you need to know to start your Wednesday

See the stock controversy heating up Reddit and how far an anticipated East Bay biotech development has come in this morning's roundup......»»

Category: topSource: bizjournalsJan 27th, 2021

Everything Jim Cramer said about the stock market on "Mad Money," including Warren Buffett advice, retail roundup

CNBC's Jim Cramer recalled Warren Buffett's iconic long-term investment advice from the 2008 financial crisis and relayed what it means for the market today......»»

Category: topSource: madmoneyMar 5th, 2020

Top Ten: Weekend roundup: How to retire in a beautiful beach town on a budget

Also, topsy-turvy Tesla stock, dire warnings for the stock market and what you need to know about new IRA rules under the Secure Act......»»

Category: topSource: marketwatchFeb 7th, 2020

These 10 global stock markets are surging the most as US-Iran tensions settle — headlined by huge gains in Turkey

Murad Sezer/Reu.....»»

Category: topSource: businessinsiderJan 9th, 2020

Top Ten: Weekend roundup: Where to retire on $5 million, outside California | Tesla’s surprise | A Nobel Prize and biotech stocks

Also, a warning about free stock trades......»»

Category: topSource: marketwatchNov 2nd, 2019

Top Ten: Weekend roundup: Worst states for taxes | Living on Social Security in a coastal city | A FIRE alternative

Also, the “best” stock sector and the meaning of Schwab’s big move......»»

Category: topSource: marketwatchOct 4th, 2019

Real estate roundup: A look at the Charlotte area"s latest residential projects

From townhouses and apartments to single-family homes, a plethora of projects should bring a mix of more housing options to the Charlotte area in the future. Local homebuilder Saussy Burbank is growing Charlotte's stock of townhouses with the second.....»»

Category: topSource: bizjournalsOct 2nd, 2019

Top Ten: Weekend roundup: ‘Best new ideas in money’ series continues | A better way to invest in electric cars | Housing market heats up

Also, a case for target-date funds and more dividend-stock ideas......»»

Category: topSource: marketwatchSep 6th, 2019